Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents

被引:56
作者
Lv, Kai [1 ,2 ]
You, Xuefu [1 ,2 ]
Wang, Bin [3 ]
Wei, Zengquan [4 ]
Chai, Yun [1 ,2 ]
Wang, Bo [1 ,2 ]
Wang, Apeng [1 ,2 ]
Huang, Guocheng [1 ,2 ]
Liu, Mingliang [1 ,2 ]
Lu, Yu [3 ]
机构
[1] Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China
[2] Peking Union Med Coll, Beijing 100050, Peoples R China
[3] Capital Med Univ, Dept Pharmacol, Beijing TB & Thorac Tumor Res Inst, Beijing Key Lab Drug Resistance TB Res,Beijing Ch, Beijing 101149, Peoples R China
[4] Tianjin Chase Sun Pharmaceut Co Ltd, Tianjin 301700, Peoples R China
关键词
Antitubercular agents; benzothiazinones; spiro-heterocycles; structure-activity relationships; pharmacokinetics; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; POTENT ANTIMYCOBACTERIAL ACTIVITY; D-RIBOSE 2'-EPIMERASE; DRUG TARGET; IN-VIVO; DPRE1; INHIBITORS; DESIGN; DISCOVERY; APPROVAL;
D O I
10.1021/acsmedchemlett.7b00106
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of new 8-nitro-6-(trifluoromethyl)-1,3benzothiazin-4-one(BTZ) derivatives containing a C-2 nitrogen Spiro-heterocycle moiety based on the structures of BTZ candidates BTZ043 and PBTZ169 were designed and synthesized as new antitubercular agents. Many of them were found to have excellent in vitro activity (MIC < 0.15 mu M) against the drug susceptive Mycobacterium tuberculosis H37Rv strain and two clinically. isolated multidrug-resistant strains. Compounds 11l and 11m display acceptable safety, greater aqueous solubility, and better pharmacokinetic profiles than PBTZ169, suggesting their promising potential to be lead compounds for future antitubercular drug discovery.
引用
收藏
页码:636 / 641
页数:6
相关论文
共 34 条
[1]  
[Anonymous], GLOB TUB REP 2016
[2]   Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors [J].
Batt, Sarah M. ;
Jabeen, Talat ;
Bhowruth, Veemal ;
Quill, Lee ;
Lund, Peter A. ;
Eggeling, Lothar ;
Alderwick, Luke J. ;
Fuetterer, Klaus ;
Besra, Gurdyal S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (28) :11354-11359
[3]  
Baxter E.W., 2001, Org. React, V59, P1
[4]   DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization [J].
Brecik, Miroslav ;
Centarova, Ivana ;
Mukherjee, Raju ;
Kolly, Gaelle S. ;
Huszar, Stanislav ;
Bobovska, Adela ;
Kilacskova, Emoeke ;
Mokosova, Veronika ;
Svetlikova, Zuzana ;
Sarkan, Michal ;
Neres, Joao ;
Kordulakova, Jana ;
Cole, Stewart T. ;
Mikusova, Katarina .
ACS CHEMICAL BIOLOGY, 2015, 10 (07) :1631-1636
[5]   Synthesis and in vitro antibacterial activity of 7-(4-alkoxyimino-3-amino-3-methylpiperidin-1-yl)fluoroquinolone derivatives [J].
Chai, Yun ;
Wan, Zhi-Long ;
Wang, Bo ;
Guo, Hui-Yuan ;
Liu, Ming-Liang .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (10) :4063-4069
[6]   INFECTIOUS DISEASE Approval of Novel TB Drug Celebrated-With Restraint [J].
Cohen, Jon .
SCIENCE, 2013, 339 (6116) :130-130
[7]   A NMR and theoretical study of the aggregates between alkyllithium and chiral lithium amides:: Control of the topology through a single asymmetric center [J].
Corruble, A ;
Davoust, D ;
Desjardins, S ;
Fressigné, C ;
Giessner-Prettre, C ;
Harrison-Marchand, A ;
Houte, H ;
Lasne, MC ;
Maddaluno, J ;
Oulyadi, H ;
Valnot, JY .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (51) :15267-15279
[8]   Decaprenylphosphoryl-β-D-Ribose 2′-Epimerase, the Target of Benzothiazinones and Dinitrobenzamides, Is an Essential Enzyme in Mycobacterium smegmatis [J].
Crellin, Paul K. ;
Brammananth, Rajini ;
Coppel, Ross L. .
PLOS ONE, 2011, 6 (02)
[9]   New agents for the treatment of drug-resistant Mycobacterium tuberculosis [J].
Hoagland, Daniel T. ;
Liu, Jiuyu ;
Lee, Robin B. ;
Lee, Richard E. .
ADVANCED DRUG DELIVERY REVIEWS, 2016, 102 :55-72
[10]   Tuberculosis success [J].
Jones, Dan .
NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (03) :175-176